德勤中国高科技高成长项目全国主管合伙人赵锦东说道："在企业推动科技与创新时，人才、资本与AI 研发投入成为三大关键驱动力。调研显示，23%的中国50强企业和66%的明日之星企业，AI研发投入占 营收的50%以上。但无论是中国50强企业还是明日之星企业，都面临着高技术人才的短缺、AI技术在业 务场景中的应用不足以及研发成本攀升等挑战。然而，核心技术自主研发、产品的快速迭代和多元化融 资正成为企业韧性发展的突破口。此外，越来越多的科技企业将AI智能体从工具化向数字员工化演 进，以全面提升效率、创新力与竞争优势。" 赵锦东认为，在这趋势的带动下，中国科技行业的高潜赛道已向多领域拓展布局，企业凭借技术创新与 生态化场景落地，在创新提质中抢占发展高地。目前，中国科技正在从AI全面渗透、算力与连接技术 迭代、机器人技术爆发、能源与绿色科技突破以及空间与低空经济崛起这五个方面加强技术创新。 本报讯(记者张文湘见习记者占健宇)12月16日，德勤中国对外发布《2025德勤中国高科（600730）技高 成长50强及明日之星报告》(以下简称"报告")。报告显示，今年中国50强企业三年累计营收增长率的平 均值为490%。营收规模方面 ...

Core Insights - BMC Ruimaite has established itself as a leading domestic enterprise in the respiratory health sector, focusing on independent research and development to overcome the challenges posed by international competitors [2][3] - The company aims to evolve from providing single devices to offering comprehensive respiratory health solutions, enhancing user experience and accessibility [3] Group 1: Company Development - BMC Ruimaite's production facility in Tianjin is actively manufacturing home ventilators, which are set to be distributed to over 100 countries and regions globally [2] - The company has made significant advancements in core technology, particularly in the development of the fan, which is considered the "heart" of the ventilator, achieving performance levels comparable to top international standards [2] Group 2: Strategic Vision - The company envisions becoming the preferred platform for global respiratory health management, leveraging its accumulated technology, products, and services to meet user needs more effectively [3] - A collaborative project involving BMC Ruimaite, its subsidiary Tianjin Yihe Jiaye, and Beijing Chaoyang Hospital has been awarded the first prize in the "Science and Technology Progress Award" by the Tianjin Science and Technology Bureau, highlighting the importance of integrating medical and engineering expertise [3]

Core Insights - The article highlights the strategic advancements and achievements of Beijing Ruimait Medical Technology Co., Ltd. in the respiratory health sector, showcasing its position as a leading domestic manufacturer of home ventilators in China and the second globally [1] Group 1: Technological Innovation and Market Expansion - Ruimait has established itself as the only Chinese company among the top five global home ventilator manufacturers, focusing on respiratory issues such as COPD and obstructive sleep apnea since its founding in 2001 [2] - The company has achieved significant technological milestones, including being the first Chinese brand to receive FDA certification for home ventilators in 2012, and has accumulated 932 domestic and international patents by June 30, 2025 [2][3] - Ruimait's home ventilators have sold over 3 million units globally, with more than 10 million masks sold, demonstrating its extensive market reach [2] Group 2: Commitment to R&D and Industry Standards - The company emphasizes its commitment to independent R&D, particularly in core technologies, which has led to the localization of key components and significant improvements in product performance [3] - Ruimait has contributed to the establishment of 38 industry standards, enhancing the quality and competitiveness of Chinese respiratory health products in the global market [4] Group 3: Ecosystem Development and Comprehensive Solutions - Ruimait is expanding its capabilities beyond single devices to comprehensive respiratory health management solutions, aiming to become a preferred platform for global respiratory health management [5] - The introduction of the "smart mobile oxygen supply combination scheme" reflects the company's understanding of user needs and its ability to integrate technology across various products [6] - The establishment of a respiratory health management cloud platform in 2015 has enabled remote monitoring and intervention, transforming traditional respiratory devices into integrated management solutions [6] Group 4: Clinical Integration and User-Centric Approach - The integration of medical and engineering expertise is crucial for developing products that meet local healthcare needs, as emphasized by clinical experts [7] - Ruimait's product evolution from single devices to comprehensive solutions across various settings demonstrates its commitment to enhancing patient quality of life and effective health management [8]

Core Viewpoint - Core technologies cannot be bought or obtained through shortcuts, and there is a strong opposition to "disguised" domestic technologies. Huawei is regarded as the greatest company in China at present [1]. Group 1: Opposition to "Disguised" Domestic Technologies - There is a concern about the prevalence of technologies that are foreign but presented as domestic by "disguising" them, which poses significant security risks [3]. - The use of such disguised technologies can lead to dependency, where foreign entities can control or disrupt operations remotely, creating a major risk for users [3]. Group 2: Core Technologies Must Be Developed Locally - Core technologies must be developed from scratch, as they cannot be acquired from abroad. Historical examples illustrate that foreign companies would not sell advanced technology to China until domestic capabilities reached a certain level [4]. - China's advancements in supercomputing, which have maintained a leading position globally for 16 consecutive years, are attributed to self-developed chips, operating systems, and software, ensuring independence from foreign control [4]. Group 3: Huawei as a Model for Success - Huawei is highlighted as a prime example of a successful high-tech enterprise in China, demonstrating resilience and innovation despite challenging circumstances [5]. - The company has effectively consolidated its innovative capabilities over the past 30 years, becoming a respected name internationally [5]. - The current geopolitical climate poses challenges for core technology companies, but Huawei's long-term accumulation of knowledge and resources positions it to withstand these pressures [6].